超声引导下微波消融治疗早期泡型肝包虫病患者疗效初步研究*

doi:10.3969/j.issn.1672-5069.2020.04.035

摘要/Abstract

摘要： 目的探讨采用超声引导下微波消融治疗早期泡型肝包虫病患者的疗效。方法 2018年6月～2019年10月我院诊治的早期泡型肝包虫病患者50例,采用随机数字表法将患者分为对照组(n=25例)和观察组(n=25例)。在对照组,采用常规开腹手术,在观察组,采用超声引导下微波消融治疗,术后随访1年。结果观察组治疗总有效率为92.0%,显著高于对照组的80.0%(P<0.05);术后1 w,观察组血清总胆红素水平为(16.7±1.6)μmol/L,与对照组【(14.2±1.4)μmol/L,P>0.05】比,差异无统计学意义,血清丙氨酸氨基转移酶水平为(140.8±52.4)U/L,显著低于对照组【(194.7±63.2)U/L,P<0.05】,血清GGT水平为(95.1±10.2)U/L,显著低于对照组【(102.4±11.3)U/L,P<0.05】,而血清ALB水平为(35.7±3.4)g/L,显著高于对照组【(32.9±3.5)g/L,P<0.05】;在随访期间,观察组并发症发生率为4.0%,显著低于对照组的36.0%(P＜0.05)。结论采用超声引导下微波消融治疗早期泡型肝包虫病患者可获得很好的临床疗效,可显著降低并发症发生率,值得临床进一步研究。

关键词: 肝包虫病, 超声引导, 微波消融, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy and safety of ultrasound-guided percutaneous microwave ablation for the treatment of patients with hepatic alveolar echinococcosis. Methods 50 patients with early hepatic vesicular echinococcosis were treated in our hospital between June 2018 and October 2019, and they were divided randomly into control (n=25) and observation group (n=25). The patients in the control group were treated with conventional open surgery, and those in the observation group were treated with microwave ablation under ultrasound guidance. The followed-up period was 1 year. Results The total effective rate in the observation group was 92.0%, which was significantly higher than that in the control group [80.0%, P<0.05]; 1 week after operation, serum total bilirubin level in the observation group was (16.7±1.6) μmol/L, which was not significantly different as compared to that in the control group [(14.2±1.4) μmol/L, P<0.05], serum alanine aminotransferase level in the observation group was (140.8±52.4 ) U/L, which was significantly lower than [(194.7 ± 63.2) U/L, P<0.05]in the control group, and serum GGT level was (95.1±10.2) U/L, which was significantly lower than in the control group [(102.4±11.3) U/L, P<0.05], while serum albumin level in the observation group was (35.7±3.4) g/L, which was significantly higher than that in the control group [ (32.9±3.5) g/L, P<0.05]; the complication rate in the observation group during the follow-up period was 4.0%, significantly lower than36.0%(P＜0.05)in the control. Conclusion The ultrasound-guided microwave ablation in the treatment of patients with hepatic alveolar echinococcosis is efficacious, which might reduce the incidence of post-operational complications.

Key words: Hepatic alveolar echinococcosis, Ultrasound-guidance, Microwave ablation, Therapy

魏倩, 王艳, 游岚岚, 苟博. 超声引导下微波消融治疗早期泡型肝包虫病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 593-596.

Wei Qian, Wang Yan, You Lanlan, et al. Efficacy and safety of ultrasound-guided percutaneous microwave ablation for the treatment of patients with hepatic alveolar echinococcosis[J]. Journal of Practical Hepatology, 2020, 23(4): 593-596.

参考文献

[1]韩为清, 崔佳宾, 杨予川. 应用F-FDG PET/CT检查评价肝泡型包虫病肝内病灶活性研究. 实用肝脏病杂志, 2020, 23(1): 110-113.
[2]Chen KF, Tong YY, Wang R, et al. The choose of different surgical therapies of hepatic alveolar echinococcosis: a single-center retrospective case-control study. Medicine, 2018, 97(8): 33-34.
[3]Tiemin J, Qiang G, Bo R, et al.Hydatid cyst of the thyroid gland with tracheal fistula: A case report and review of the literature. Exp Ther Med, 2019, 18(1): 573-579.
[4]Zuo RQ,Chen XH, Wang H, et al. Improved experimental model of hepatic cystic hydatid disease resembling natural infection route with stable growing dynamics and immune reaction. World J Gastroenterol, 2017, 23(45): 7989-7999.
[5]郭建琴, 华国勇, 张晓敏, 等. 超声引导经皮肝穿刺微波消融肝泡型包虫的初步临床研究. 中华超声影像学杂志, 2017, 21(10):913-914.
[6]才让卓玛, 南嘉格列, 李晓君, 等. 常规彩超与超声造影诊断肝泡型包虫病效能比较. 实用肝脏病杂志, 2018, 21(2): 305-306.
[7]Mar S L, Adriano C, Roberto C, et al. Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: compounds and therapeutic targets. PLoS Negl Trop Dis, 2018,12(4): 6422-6423.
[8]李林昌. 泡型肝包虫病多脏器侵犯MRI表现. 实用肝脏病杂志, 2019, 22(4): 585-588.
[9]Yangdan C, Lingqiang Z, Bin R, et al.Efficacy and safety of ultrasound-guided percutaneous microwave ablation for the treatment of hepatic alveolar echinococcosis: a preliminary study. Medicine, 2017, 96(27): 7137-7138.
[10]Qiancheng D, Yanyan W, Mengzhao Z, et al.A new treatment strategy for end-stage hepatic alveolar echinococcosis: IVC resection without reconstruction. Sci Rep, 2019, 9(10): 9419-9420.
[11]Mesut B, Merve G K, Sabri Y, et al.Multimodality imaging in diagnosis and management of alveolar echinococcosis: an update. Diagn Interv Radiol, 2016, 22(3): 247-256.
[12]Ghodratollah M, Abbas A, Reza S, et al.Difficulties in the diagnosis and management of alveolar hydatid disease: a case series. Caspian J Intern Med, 2016, 7(1): 52-56.
[13]Chuanshan Z, Yingmei S, Shuting Y, et al.T-cell tolerance and exhaustion in the clearance of Echinococcus multilocularis: role of inoculum size in a quantitative hepatic experimental model. Sci Rep, 2017, 7(10): 11153-11154.
[14]Guo CH,Wang JY, Sun F, et al. Field evaluation of an immunochromatographic test for diagnosis of cystic and alveolarechinococcosis. Parasit Vectors, 2018, 11(10): 311-312.
[15]Yang XW, Qiu YW,Wang WT, et al. Risk factors and a simple model for predicting bile leakage after radical hepatectomy in patients with hepatic alveolar echinococcosis. Medicine, 2017, 96(46): 8774-8775.
[16]Stefanie K, Irmgard E K, AlexanderL, et al. Exploring the limits of hepatic surgery for alveolar echinococcosis-10-years’ experience in an endemic area of austria. Eur Surg, 2019, 51(4): 25-28.
[17]Asenov Y, Akin M, Tekant Y, et al. Observed or predicted albendazole hepatotoxicity as an indication for a resection procedure in hepatic hydatid disease-a short series of cases. Chirurgia, 2019, 114(4):189-190.
[18]Virginia V T, Ángela R A, Moncef B, et al. Recurrence of cystic echinococcosis in an endemic area: a retrospective study. BMC Infect Dis, 2017, 17(10): 455-456.
[19]陈勇. 超声引导经皮经肝胆道穿刺引流术治疗肝泡型包虫病合并梗阻性黄疸的疗效分析. 中华普通外科学文献(电子版), 2018, 12(5): 346-349.
[20]Ao CS, Ke JG, Huang XM, et al. Comparison of Echinococcus multilocularis and Echinococcus granulosus hydatid fluid proteome provides molecular strategies for specialized host-parasite interactions. Oncotarget, 2017, 8(57): 97009-97024.

超声引导下微波消融治疗早期泡型肝包虫病患者疗效初步研究^*

Efficacy and safety of ultrasound-guided percutaneous microwave ablation for the treatment of patients with hepatic alveolar echinococcosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	卓丽, 许敏, 邓浩辉. 阿舒瑞韦联合达拉他韦治疗慢性丙型肝炎患者初步疗效及其病毒准种变化和耐药变异特征分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 504-507.
[2]	黄丽华, 杨正兵, 谭礼让. 熊去氧胆酸联合非诺贝特治疗PBC患者血清TGF-β、IFN-γ和IL-10水平变化^*[J]. 实用肝脏病杂志, 2020, 23(4): 520-523.
[3]	齐敬聪, 邢文静, 杜洋, 高辰玮. 熊去氧胆酸联合微生态制剂治疗原发性胆汁性胆管炎患者对肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 524-527.
[4]	侯光华, 胡启江, 徐美华, 朱绍咏, 黄波. 多烯磷脂酰胆碱联合二甲双胍和非诺贝特治疗NAFLD患者血清Pygo2和血脂水平变化^*[J]. 实用肝脏病杂志, 2020, 23(4): 528-531.
[5]	周娜, 蒋磊, 吴冰冰. 阿托伐他汀治疗NAFLD患者对肝脂肪变和外周血Treg/Th17细胞的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 532-535.
[6]	陈曦, 陈照林, 董静, 宋海燕, 刘波, 张骏飞, 陈从新. 脐带间充质干细胞联合双重血浆分子吸附治疗慢加急性肝衰竭患者临床效果初步观察[J]. 实用肝脏病杂志, 2020, 23(4): 544-547.
[7]	张静, 周新民. 应用重组人血小板生成素减少肝硬化患者术前血小板输注疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 552-555.
[8]	陈照林, 董静, 宋海燕, 刘波, 张骏飞. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者临床研究[J]. 实用肝脏病杂志, 2020, 23(4): 556-559.
[9]	孟海生, 胡冬梅, 王海涛, 顾金凤, 赵静, 梁啸寒. 应用超声单模态融合成像技术指导微波消融治疗原发性肝癌即时疗效评价的价值研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 572-575.
[10]	全亚宁, 商晓杰, 孟璇, 高榆秀. 实时超声造影和融合影像导航下微波消融与手术治疗小肝癌患者疗效比较^*[J]. 实用肝脏病杂志, 2020, 23(4): 581-584.
[11]	郑雪, 宣之东, 王玉, 张丽静. 超声联合CT检查在肝恶性肿瘤射频消融治疗中的应用价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(4): 589-592.
[12]	艾国,王鸣,朱纪玲,邢铭友. 应用N-乙酰半胱氨酸治疗慢性乙型肝炎重度患者临床疗效初步研究[J]. 实用肝脏病杂志, 2020, 23(3): 336-339.
[13]	方利娟,吴雄飞. 恩替卡韦治疗乙型肝炎病毒携带者合并肺结核患者临床疗效分析[J]. 实用肝脏病杂志, 2020, 23(3): 340-343.
[14]	符垂师,张杰伟. α干扰素联合利巴韦林治疗儿童丙型肝炎患者病毒学应答率分析[J]. 实用肝脏病杂志, 2020, 23(3): 344-347.
[15]	杜颖,姜志红,吴雅玲. 雷公藤多甙联合异甘草酸镁治疗儿童自身免疫性肝炎疗效及其对血清IL-17和CXCL10水平的影响[J]. 实用肝脏病杂志, 2020, 23(3): 348-351.